Brian Mckelligon Sells 7,500 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock

Akoya Biosciences, Inc. (NASDAQ:AKYAGet Free Report) CEO Brian Mckelligon sold 7,500 shares of the firm’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $2.01, for a total value of $15,075.00. Following the transaction, the chief executive officer now directly owns 224,733 shares of the company’s stock, valued at approximately $451,713.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Brian Mckelligon also recently made the following trade(s):

  • On Wednesday, March 20th, Brian Mckelligon sold 7,500 shares of Akoya Biosciences stock. The shares were sold at an average price of $4.97, for a total transaction of $37,275.00.
  • On Wednesday, March 13th, Brian Mckelligon sold 7,500 shares of Akoya Biosciences stock. The shares were sold at an average price of $4.94, for a total transaction of $37,050.00.

Akoya Biosciences Stock Performance

Shares of AKYA stock opened at $2.05 on Friday. The company has a market capitalization of $101.25 million, a price-to-earnings ratio of -1.39 and a beta of 1.31. Akoya Biosciences, Inc. has a 1-year low of $1.88 and a 1-year high of $8.80. The company has a current ratio of 3.07, a quick ratio of 2.38 and a debt-to-equity ratio of 2.33. The stock’s fifty day simple moving average is $3.42 and its 200-day simple moving average is $4.45.

Akoya Biosciences (NASDAQ:AKYAGet Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.05). The business had revenue of $18.35 million for the quarter, compared to analysts’ expectations of $24.13 million. Akoya Biosciences had a negative net margin of 72.68% and a negative return on equity of 111.80%. On average, sell-side analysts predict that Akoya Biosciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Silvercrest Asset Management Group LLC acquired a new stake in shares of Akoya Biosciences during the 1st quarter valued at $2,724,000. Vanguard Group Inc. boosted its position in Akoya Biosciences by 3.3% during the first quarter. Vanguard Group Inc. now owns 1,454,288 shares of the company’s stock valued at $6,821,000 after purchasing an additional 46,131 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in Akoya Biosciences by 28.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 674,787 shares of the company’s stock valued at $3,293,000 after purchasing an additional 149,164 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Akoya Biosciences by 291.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,408 shares of the company’s stock worth $51,000 after purchasing an additional 7,746 shares during the last quarter. Finally, CIBC Asset Management Inc increased its position in Akoya Biosciences by 176.0% in the 4th quarter. CIBC Asset Management Inc now owns 115,644 shares of the company’s stock worth $564,000 after purchasing an additional 73,737 shares during the last quarter. 79.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AKYA has been the subject of several recent research reports. Canaccord Genuity Group cut their target price on shares of Akoya Biosciences from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, May 14th. Morgan Stanley dropped their price target on Akoya Biosciences from $8.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, June 3rd. BTIG Research reduced their price objective on Akoya Biosciences from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, May 14th. UBS Group boosted their target price on Akoya Biosciences from $7.00 to $7.50 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, JPMorgan Chase & Co. decreased their price target on Akoya Biosciences from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Akoya Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.21.

Get Our Latest Report on AKYA

About Akoya Biosciences

(Get Free Report)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

Featured Articles

Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.